CN101816715B - 使用hplc法测定肾衰宁胶囊中丹参素含量的方法 - Google Patents
使用hplc法测定肾衰宁胶囊中丹参素含量的方法 Download PDFInfo
- Publication number
- CN101816715B CN101816715B CN2009102182408A CN200910218240A CN101816715B CN 101816715 B CN101816715 B CN 101816715B CN 2009102182408 A CN2009102182408 A CN 2009102182408A CN 200910218240 A CN200910218240 A CN 200910218240A CN 101816715 B CN101816715 B CN 101816715B
- Authority
- CN
- China
- Prior art keywords
- shenshuaining
- danshensu
- capsules
- water
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000009961 Shenshuaining Substances 0.000 title claims abstract description 60
- 239000002775 capsule Substances 0.000 title claims abstract description 60
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 title claims abstract description 32
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 title claims abstract description 32
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title claims abstract description 28
- 238000004128 high performance liquid chromatography Methods 0.000 title claims abstract description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 75
- 229960000583 acetic acid Drugs 0.000 claims abstract description 24
- 239000007788 liquid Substances 0.000 claims abstract description 19
- 239000012362 glacial acetic acid Substances 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000005457 ice water Substances 0.000 claims abstract description 11
- 238000005303 weighing Methods 0.000 claims abstract description 9
- 230000035945 sensitivity Effects 0.000 claims abstract description 3
- 239000013558 reference substance Substances 0.000 claims description 27
- ZMMKVDBZTXUHFO-DDWIOCJRSA-M sodium;(2r)-3-(3,4-dihydroxyphenyl)-2-hydroxypropanoate Chemical compound [Na+].[O-]C(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 ZMMKVDBZTXUHFO-DDWIOCJRSA-M 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 18
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 238000004458 analytical method Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 230000014759 maintenance of location Effects 0.000 claims description 3
- 238000005138 cryopreservation Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000000243 solution Substances 0.000 abstract description 21
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract description 4
- 239000011734 sodium Substances 0.000 abstract description 4
- 229910052708 sodium Inorganic materials 0.000 abstract description 4
- 239000012085 test solution Substances 0.000 abstract 3
- 238000002604 ultrasonography Methods 0.000 abstract 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 22
- 239000003814 drug Substances 0.000 description 22
- 238000012360 testing method Methods 0.000 description 12
- 229940079593 drug Drugs 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 240000007164 Salvia officinalis Species 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 235000005412 red sage Nutrition 0.000 description 5
- -1 N-acetyl-β-D-glucosamine glucoside Chemical class 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000009413 insulation Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000010812 external standard method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 238000001303 quality assessment method Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000008327 renal blood flow Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 241000427159 Achyranthes Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 240000004980 Rheum officinale Species 0.000 description 1
- 235000008081 Rheum officinale Nutrition 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 244000182022 Salvia sclarea Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
批号 | 20090814 | 20090921 | 20090927 |
平均含量(mg/g) | 12.199 | 11.546 | 12.381 |
样品编号 | S1 | S2 | S3 | S4 | S5 | S6 | S7 | S8 | S9 | S10 | S11 | S12 | S13 | 对照指纹图谱 |
相似度 | 0.986 | 0.984 | 0.979 | 0.917 | 0.905 | 0.913 | 0.969 | 0.948 | 0.973 | 0.987 | 0.988 | 0.962 | 0.943 | 1.000 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009102182408A CN101816715B (zh) | 2009-11-24 | 2009-11-24 | 使用hplc法测定肾衰宁胶囊中丹参素含量的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009102182408A CN101816715B (zh) | 2009-11-24 | 2009-11-24 | 使用hplc法测定肾衰宁胶囊中丹参素含量的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101816715A CN101816715A (zh) | 2010-09-01 |
CN101816715B true CN101816715B (zh) | 2012-03-28 |
Family
ID=42652092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009102182408A Active CN101816715B (zh) | 2009-11-24 | 2009-11-24 | 使用hplc法测定肾衰宁胶囊中丹参素含量的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101816715B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103071006B (zh) * | 2013-02-07 | 2014-10-22 | 云南理想药业有限公司 | 一种治疗肾功能衰竭中药的制备方法 |
CN103592392B (zh) * | 2013-11-25 | 2015-02-11 | 山西振东安特生物制药有限公司 | 脑震宁制剂中的丹参素含量测定方法 |
CN105486790B (zh) * | 2015-11-18 | 2018-06-19 | 山西德元堂药业有限公司 | 肾衰宁颗粒的指纹图谱检测方法 |
CN111198234A (zh) * | 2019-12-31 | 2020-05-26 | 安领生物医药(苏州)有限公司 | 测定犬血浆中Sodium Danshensu和Prunasin的浓度的方法 |
CN114636760B (zh) * | 2020-12-15 | 2024-01-02 | 云南雷允上理想药业有限公司 | 一种治疗肾脏疾病的中药组合物的指纹图谱建立方法及其应用 |
-
2009
- 2009-11-24 CN CN2009102182408A patent/CN101816715B/zh active Active
Non-Patent Citations (1)
Title |
---|
张明.中药肾衰宁颗粒的剂型改革与质量标准研究.《中药肾衰宁颗粒的剂型改革与质量标准研究》.2006,14. * |
Also Published As
Publication number | Publication date |
---|---|
CN101816715A (zh) | 2010-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101816715B (zh) | 使用hplc法测定肾衰宁胶囊中丹参素含量的方法 | |
CN104614456A (zh) | 一种同时检测血浆中脑心通胶囊主要成分的方法 | |
CN103954719B (zh) | 小儿消积止咳口服液hplc指纹图谱的建立方法 | |
CN102928523B (zh) | 一种野菊花指纹图谱的测定方法和野菊花的检测方法 | |
CN102038728A (zh) | 灯盏细辛药材的质量控制方法 | |
CN103207255A (zh) | 一种脑心通胶囊的含量检测方法 | |
CN104730171A (zh) | 一种中药复方制剂中赤芍、金银花多指标成分含量测定方法 | |
CN101028460B (zh) | 一种中药制剂金嗓清音丸的质量检测方法 | |
CN103969350A (zh) | 一种穿王消炎胶囊hplc指纹图谱的建立方法 | |
CN104316613A (zh) | 一种疏风解毒胶囊指纹图谱的建立方法 | |
CN104849375B (zh) | 橘红痰咳制剂的检测方法 | |
CN104502485A (zh) | 由穿山龙和刺五加为药材的中药复方制剂中6个化学成分的定量分析方法 | |
CN104007198B (zh) | 一种灵芝皇制剂hplc标准指纹图谱及其构建方法和应用 | |
CN109856270A (zh) | 一种用高效液相色谱法同时测定华盖散配方颗粒中7个指标成分的方法 | |
CN101221153B (zh) | 蜜环菌液体发酵产物hplc指纹图谱的建立方法 | |
CN103316102B (zh) | 治疗痔疮外用中药制剂的检测方法 | |
CN103424476A (zh) | 同时测定丹参多酚酸中4种水溶性成分的方法 | |
CN101961405A (zh) | 检测复方杜仲片中松脂醇二葡萄糖苷含量的方法 | |
CN102680593B (zh) | 一种行气活血、化瘀通脉的药物组合物的检测方法 | |
CN1790013B (zh) | 一种同时测定生脉注射液中原儿茶酸和5-羟甲基糠醛含量的方法 | |
CN109709222A (zh) | 一种感冒灵和复方感冒灵的成分检测方法 | |
CN101596229B (zh) | 猴耳环提取物及其制剂的质量控制方法 | |
CN103969356A (zh) | 一种丹参药材的指纹图谱的鉴别方法 | |
CN103675135A (zh) | 一种中药组合物的含量测定方法 | |
CN100522198C (zh) | 前列安通胶囊的检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Method for measuring content of Danshensu in shenshuaining capsules by utilizing HPLC method Effective date of registration: 20141117 Granted publication date: 20120328 Pledgee: China Merchants Bank Limited by Share Ltd. Kunming hi tech sub branch Pledgor: Luo Shi|YUNNAN LIXIANG PHARMACEUTICAL Co.,Ltd. Registration number: 2014990000950 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20160519 Granted publication date: 20120328 Pledgee: China Merchants Bank Limited by Share Ltd. Kunming hi tech sub branch Pledgor: Luo Shi|YUNNAN LIXIANG PHARMACEUTICAL Co.,Ltd. Registration number: 2014990000950 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Method for measuring content of Danshensu in shenshuaining capsules by utilizing HPLC method Effective date of registration: 20160520 Granted publication date: 20120328 Pledgee: China Merchants Bank Limited by Share Ltd. Kunming branch Pledgor: YUNNAN LIXIANG PHARMACEUTICAL Co.,Ltd.|Luo Shi Registration number: 2016990000388 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 650503 Kunming new town high tech industrial base, Hing Street, No. 39, Yunnan Co-patentee after: Luo Shi Patentee after: YUNNAN LEIYUNSHANG LIXIANG PHARMACEUTICAL CO.,LTD. Address before: 650106 Kunming national hi tech Industrial Development Zone, Yunnan Province, Jin Road, No. 139 Co-patentee before: Luo Shi Patentee before: YUNNAN LIXIANG PHARMACEUTICAL Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: No. 39 Huanxing Street, High tech Industrial Base, Kunming New City, Yunnan Province, 650503 Patentee after: Yunnan Leiyunshang Pharmaceutical Co.,Ltd. Country or region after: China Patentee after: Luo Shi Address before: No. 39 Huanxing Street, High tech Industrial Base, Kunming New City, Yunnan Province, 650503 Patentee before: YUNNAN LEIYUNSHANG LIXIANG PHARMACEUTICAL CO.,LTD. Country or region before: China Patentee before: Luo Shi |